Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VBI Vaccines Inc.    VBIV   CA91822J1030

VBI VACCINES INC.

(VBIV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

VBI Vaccines : selects two COVID-19 vaccine candidates for human trials

08/26/2020 | 09:17am EST

Aug 26 (Reuters) - VBI Vaccines Inc said on Wednesday it expected to begin human testing of two of its experimental COVID-19 vaccine candidates at the end of the year.

The two candidates, VBI-2901 and VBI-2902, were selected after three pre-clinical mouse studies induced neutralizing antibodies after a single dose, the company said.

The activity was analyzed using a plaque reduction neutralization test, considered the gold standard for measuring antibodies that can neutralize a virus, the company said.

VBI said its manufacturing partner, Therapure Biomanufacturing, will begin making bulk vaccines in September for use through mid-stage trials.

VBI, which was this month awarded C$56 million ($42 million) by the Canadian government to accelerate its COVID-19 vaccine development program, is one of the many companies racing to produce a safe and effective vaccine against the virus.

Many vaccine candidates are already in later stage of development.

Shares of the company rose 3.8% before the bell. ($1 = 1.32 Canadian dollars) (Reporting by Dania Nadeem in Bengaluru; Editing by Sriraj Kalluvila)


© Reuters 2020
All news about VBI VACCINES INC.
12/02VBI VACCINES : to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted ..
BU
12/01VBI VACCINES : Announces Submission of Biologics License Application to FDA for ..
BU
11/23VBI VACCINES : Announces Submission of Marketing Authorization Application for 3..
BU
11/19VBI-1901 : SNO Phase 2a Data & Clinical Update
PU
11/19VBI VACCINES : Announces Positive Interim Phase 2a Data from VBI-1901 in Recurre..
BU
11/18VBI VACCINES : Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immun..
BU
11/13VBI VACCINES : Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020
PU
11/13COVID-19 vaccine projects backed by the Canadian government
RE
11/13VBI VACCINES : Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020
BU
11/09VBI VACCINES : Announces e-Poster Presentation at the Society for Neuro-Oncology..
BU
More news
Financials (USD)
Sales 2020 1,25 M - -
Net income 2020 -44,0 M - -
Net Debt 2020 - - -
P/E ratio 2020 -15,9x
Yield 2020 -
Capitalization 777 M 777 M -
Capi. / Sales 2020 620x
Capi. / Sales 2021 71,0x
Nbr of Employees 124
Free-Float 73,7%
Chart VBI VACCINES INC.
Duration : Period :
VBI Vaccines Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VBI VACCINES INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 6,50 $
Last Close Price 3,21 $
Spread / Highest target 180%
Spread / Average Target 102%
Spread / Lowest Target -6,54%
EPS Revisions
Managers
NameTitle
Jeffrey R. Baxter President, Chief Executive Officer & Director
Steven H. Gillis Chairman
Christopher McNulty CFO, Director & Head-Business Development
David Evander Anderson Chief Scientific Officer
Francisco Diaz-Mitoma Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VBI VACCINES INC.132.61%777
MODERNA, INC.679.75%62 229
LONZA GROUP AG52.83%45 010
CELLTRION, INC.109.94%42 993
SEAGEN INC.56.86%32 484
IQVIA HOLDINGS INC.10.42%32 139